Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Relyvrio
Biotech
Amylyx discontinues rare neuro program after missing ph. 2 mark
The phase 2 portion of the trial found no difference in patients receiving AMX0035 compared to placebo at 24 weeks.
Gabrielle Masson
Aug 27, 2025 10:40am
FDA lifts clinical hold on Amylyx ALS trial
Jan 21, 2025 10:35am
Amylyx CEOs take hard lessons to rebuild the pipeline
Jul 10, 2024 7:00am
Amylyx stock slips 6% after phase 2 rare disease data drop
Apr 10, 2024 2:48pm
